Etiology for hypophosphatemia was initially thought to be secondary hyperparathyroidism given elevated parathyroid hormone (PTH) of 488 pg/mL (12 – 88 pg/mL) due to hypocalcemia in the setting of recent denosumab administration. This evidence concerns the gene PTH and secondary hyperparathyroidism.